Collectively, these findings suggest that the pharmacological inhibition of CDK12 by SR-4835 significantly impaired the metabolic flux through the TCA cycle, thereby disrupting energy generation and biosynthetic processes in the GBM cells. The gene discussed is CDK12; the disease is glioblastoma.